Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Catherine A. Sohn sold 726 shares of the business’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $135.65, for a total value of $98,481.90. Following the sale, the director now owns 9,574 shares in the company, valued at approximately $1,298,713.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of NASDAQ:JAZZ opened at $133.35 on Thursday. The firm has a market cap of $7.74 billion, a P/E ratio of 10.89, a price-to-earnings-growth ratio of 1.13 and a beta of 1.14. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.71 and a quick ratio of 3.52. The company has a 50-day simple moving average of $138.34. Jazz Pharmaceuticals PLC has a 1 year low of $113.52 and a 1 year high of $176.73.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.16 by $0.49. The company had revenue of $534.13 million for the quarter, compared to the consensus estimate of $507.23 million. Jazz Pharmaceuticals had a return on equity of 27.72% and a net margin of 32.99%. The firm’s revenue was up 6.7% compared to the same quarter last year. During the same period in the previous year, the business earned $3.49 EPS. Research analysts predict that Jazz Pharmaceuticals PLC will post 13.41 EPS for the current fiscal year.
JAZZ has been the topic of several recent research reports. ValuEngine raised Jazz Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 8th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a report on Wednesday. HC Wainwright reaffirmed a “hold” rating and set a $147.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 8th. Zacks Investment Research downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, May 6th. Finally, Piper Jaffray Companies set a $202.00 target price on Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, May 28th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company’s stock. Jazz Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $176.53.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
See Also: Fundamental Analysis
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.